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Background: Hyponatremia is a frequent electrolyte disorder in HIV-infected patients with a prevalence of up to
56% in the pre-cART era. Several studies have demonstrated that patients with hyponatremia are at an increased
risk of death. We aimed to investigate the prevalence of hyponatremia in the recent cART-era and evaluate its
association with mortality.
Methods: Single-center retrospective cohort study. A total of 1196 newly diagnosed and cART-naïve HIV patients
followed at the AIDS Reference Center, St Pierre University Hospital in Brussels, Belgium, between 1 January 1998
and 31 December 2013 were included. Hyponatremia was defined as a baseline natremia lower than 135 mmol/l.
The outcome of interest was the occurrence of death.
Results: In this study 177 (14.8%) patients had hyponatremia at baseline with a median natremia of 132.0 mmol/l
[interquartile range (IQR) 130.0-134.0 mmol/l]. Hyponatremic patients had a lower CD4 cell count (207.5 ± 197.7/μl vs
400.4 ± 277.0/μl; P < 0.0001) and a higher prevalence of AIDS (50.3% vs 12.4%; P < 0.0001) compared to normonatremic
patients. A significantly higher proportion of patients with hyponatremia were hospitalized at first contact (72.3% vs
20.0%; P < 0.0001). During the follow-up hyponatremic patients had a shorter median time to a first hospitalization (2.0
IQR [0.0-12.0] months vs 13.0 IQR [2.0-29.0] months; P = 0.001) and an increased incident hospitalization rate (785/1000
patient-years, 95% CI 725–845 vs 370/1000 patient-years, 95% CI 352–388; P < 0.0001]. The incident mortality rate was
28.3/1000 patient-years (95% CI 18.15-42.16) in patients with hyponatremia compared to 9.33/1000 patient-years
(95% CI 6.63-12.75) in normonatremic patients (P < 0.0001). Three-year cumulative survival rates were 85.8% ± 3.0% in
hyponatremic patients and 96.3% ± 0.7% in normonatremic patients (log-rank P < 0.0001). However, in a multivariate
Cox model adjusting for other risk factors such as AIDS, CD4 count < 350/μl and hepatitis C, hyponatremia was no
longer a predictor for patient death (hazard ratio: 1.03, 95% CI 0.54-1.97; P = 0.935).
Conclusions: Hyponatremia is a marker of severity of HIV-disease but not an independent risk factor for mortality.
HIV-patients with a low serum sodium at baseline might benefit from a close follow-up to improve outcomes.
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Hyponatremia, commonly defined as a serum sodium
concentation < 135 mmol/l, is the most common electro-
lyte abnormality encountered in clinical practice. In the
general population its prevalence is estimated 4–7% in an
ambulatory setting and 15–30% in hospital care [1, 2].
Several studies have shown that hyponatremia is associ-
ated with an increased risk of death both in hospitalized
and in ambulatory patients [3, 4]. This has classically been
demonstrated in patients with heart failure [5] and cirrho-
sis [6] where hyponatremia seems to reflect the severity of
the underlying disease, but recent data suggest that
chronic and mild hyponatremia in the general population
is also associated with mortality [7]. Several conditions
may predispose to the development of hyponatremia in
human immunodeficiency virus (HIV)-positive patients:
severe volume depletion which is most often caused by
gastrointestinal fluid losses such as diarrhea; the syndrome
of inappropriate antidiuresis usually due to drugs (most
common antidepressants, anticonvulsants but also pyrazi-
namide, ethambutol) [8], malignancy, pulmonary and cen-
tral nervous system infections (such as Pneumocystis
jiroveci infection, neurosyphilis or toxoplasmosis) [9, 10];
and adrenal insufficiency which is a less common cause.
In HIV-infected patients with the acquired immunodefi-
ciency syndrome (AIDS) or AIDS-related complex (ARC)
a prevalence of 35–56% of hyponatremia has been ob-
served in several studies performed before the era of com-
bined antiretroviral therapy (cART) [9, 11, 12]. Tang et al.
demonstrated in a prospective study of 212 in-patients
with AIDS or ARC that on average hospitalizations lasted
8 days longer in those with hyponatremia than in those
with normal serum sodium concentrations and that pa-
tients in the hyponatremic group had nearly two-fold
higher risk of death [12]. In the pre-cART era hyponatre-
mia in ambulatory HIV-positive patients had also been re-
ported to be associated with a reduction of median
survival from 39 months to 11.5 months as compared to
HIV-positive patients without hyponatremia [13].
In 1997 the introduction of the combined antiretro-
viral therapy resulted in a 60–80% decline of AIDS, mor-
tality and hospitalisations in regions were these
medications have been made available to patients [14].
Since then little is known about the prevalence of hypo-
natremia and its association with mortality in HIV pa-
tients. Although incidences of hyponatremia in HIV
patients were previously high and strongly associated
with an increased risk of death, treatment has changed
dramatically with possible effects on the association of
hyponatremia with mortality. The aims of our study
were to investigate the prevalence of hyponatremia in
the more recent cART-era in a single-center cohort of
HIV-positive patients with long term follow up and to
provide a detailed description of health conditionsassociated with hyponatremia which might act as con-
founders of the association between hyponatremia and
death. The hypothesis of our study was that, similar to
the general population, hyponatremia is an independent
risk factor for death of HIV-positive patients after
adjusting for confounding risk factors.
Methods
Study design and participants
We conducted a retrospective cohort study including all
newly diagnosed and cART-naïve HIV patients followed at
the AIDS Reference Center St Pierre University Hospital
in Brussels, Belgium, between 1 January 1998 and 31
December 2013. During this period a total of 4195 pa-
tients entered the Brussels St Pierre Cohort. We excluded
2999 patients: 1247 non cART-naïve patients and 1752
patients without available baseline natremia. A total of
1196 patients were included in the study and initiated on
cART during the follow up period. The Brussels St Pierre
Cohort collects information about all the adult HIV-
infected patients (≥18 years) ever seen at St Pierre Univer-
sity Hospital in Brussels for consultation or for
hospitalization. Types of data collected include demo-
graphic, therapeutic and laboratory data, clinical events
and health services utilization. The follow-up interval for
data collection including CD4 and viral load determin-
ation is every 3 to 4 months. Prospective data are collected
through structured questionnaires and medical records.
Data quality is assured by an automatic check of data val-
idity through the data system and data validation by a
physician. The Brussels St Pierre cohort participates in the
DAD, EuroSIDA and COHERE cohorts and has been vali-
dated by numerous publications [15–17].
Data definition
Exposure of interest: Hyponatremia was defined as a
serum sodium concentration lower than 135 mmol/l and
was used to divide the population in two exposure cat-
egories: hyponatremic patients and normonatremic
patients (natremia ≥ 135 mmol/l). The serum sodium
concentration was measured by indirect ion selective
electrode potentiometry (Roche) and recorded automat-
ically at baseline, the first available laboratory value at
patient inclusion in the cohort. Common treatment
strategies for hyponatremia in our clinic are etiology-
based and include restricting fluid intake, hypertonic salt
administration and increasing solute intake with urea or
a combination of low-dose loop diuretics and oral so-
dium chloride.
Collection of potential confounding variables
The following demographic data were extracted for all in-
cluded patients: age, gender, ethnicity (black, caucasian,
other) and sexual orientation (heterosexual or homo-/bi-
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baseline values recorded by a data manager at patient in-
clusion in the cohort and validated by a physician. CD4
cell count nadir was defined as the lowest CD4 cell count
(/μl) measured prior to patient inclusion in the cohort.
The AIDS stage at inclusion was defined according to the
criteria of the Centers for Disease Control and Prevention
[18]. A serum hemoglobine ≤ 14 g/dl for men and ≤ 12 g/
dl for women defined anemia. Results from the EuroSIDA
study group have previously reported that anemia is a
strong independent prognostic marker for death in HIV-
infected patients from across Europe [19].
Hyperlipidemia was defined according to the National
Cholesterol Education Program (NCEP) Guidelines
(total cholesterol ≥ 200 mg/dl or LDL ≥ 130 mg/dl or
triglycerids ≥ 150 mg/dl) [20] and by the intake of lipid-
lowering drugs (statines or fibrates). Patients were
considered diabetic in case of insuline therapy, oral anti-
diabetics or HbA1c ≥ 6.5% [21]. The presence of a hepa-
titis B surface antigen defined active hepatitis B disease.
Patients were considered hepatitis C positive if anti-
hepatitis C antibodies were present. An analysis of data
from the CASCADE collaboration demonstrated that in-
dividuals co-infected with HIV and hepatitis C have a
higher risk of death from HIV or liver disease than pa-
tients infected with only HIV [22]. As a validated indir-
ect marker of liver fibrosis the FIB-4 index was
calculated according to the following formula: FIB-4 =
age (years) × AST [U/L]/(platelets [109/L] × (ALT [U/
L])1/2) [23]. A cut-off > 3.25 was used because it predicts
a significant liver fibrosis with a positive predictive value
of 65% and a specificity of 97% [23]. The FIB-4 index
has recently been shown to be an independent predictor
of liver-related death in HIV infected patients initiating
antiretroviral therapy [24].
Follow up period
During the 15-year follow up the characteristics of the
patient population and prevalence of hyponatremia were
likely to change. We therefore subdivided the observa-
tion period into two succcessive sub-periods (1998–2004
and 2005–2013) and tested whether these were associ-
ated with the exposure and outcome of interest.
Outcomes of interest
The occurence of death in the follow-up period was the
outcome of interest. The CoDe Coding Causes of Death
(CoDe) in HIV protocol was used as a classification sys-
tem for the causes of death (http://www.cphiv.dk/Tools-
Standards/CoDe/) which were subdivided in HIV-related
and non HIV-related deaths. A secondary outcome was
the number of hospitalizations during the follow-up
period. Causes of hospital admission were divided into
20 categories, which were the most commonly reportedin the scientific literature [25]: AIDS-related, malnutri-
tion/wasting, parasitic infections, bacterial infections,
malignancies, drug toxicities, neurological, cardiovascu-
lar, renal, endocrine/metabolic, haematological, respira-
tory, digestive, liver, viral, skin/soft tissue, psychiatric
disorders gynaecological, other causes or unknown. Pa-
tients were considered lost to follow-up in case of no
contact for more than one year.
Statistical analysis
Patient characteristics were described using mean and
standard deviation or median and interquartile range
(IQR) for continuous data, and frequencies with percent-
ages for qualitative data. Hypothesis testing for differ-
ences between the two exposure categories was done
with the Mann–Whitney U test for continuous data and
the Chi-square test or Fishers exact test for categorical
data. In case of missing data only the available data was
analyzed. Patient survival was estimated with the
Kaplan-Meier method and the null hypothesis of equal
survival in the two exposure categories tested using the
log-rank test. Mortality was quantified as the incidence
death rates per 1000 patient-years at risk. Time at risk
was defined as the delay between inclusion in the cohort
and patient death. Patients were censored in case of loss
to follow-up or at the end of the study period on De-
cember 31, 2013. As many patients were hospitalized
multiple times, we also calculated the incidence rate of
hospitalization without censoring the patient after the
first hospitalization. A negative binomial regression was
used to test the association.
The effect of hyponatremia and other patient charac-
teristics associated with baseline hyponatremia on pa-
tient death was first investigated by univariate Cox
proportional-hazards regression. A multivariable Cox
model was then build by including all covariates that
were significantly associated with patient death in the
univariate analysis. The assumption of proportional haz-
ards over time was verified and met by all covariates
introduced in the models. We have generated time
dependent covariates by creating interactions of the pre-
dictors and a function of survival time included in the
model. If any of these time dependent covariates were
significant then those predictors were not proportional
which was not the case in our model. A type-1 error of
<0.05 was used to reject the null hypothesis for all hy-
pothesis testing. Analysis and graphs were produced
using SAS statistical software (version 9.4; SAS Institute,
Cary, North Carolina, USA).
Ethical considerations
The procedures of data collection and measures taken to
maintain data confidentiality in the database of Brussels
St Pierre cohort have been reviewed and approved by
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consented at the time of inclusion in the cohort that
their medical data would be collected in the centre and
European databases for medical and research purposes.
Results
Baseline patient characteristics
In total 1196 HIV-infected patients were included in the
cohort with a mean age of 36.8 ± 10.7 years and a predom-
inance of men (62.8%) (Table 1; Title: Main characteristics
of hyponatremic and normonatremic patients).
Hyponatremia at baseline was present in 177 (14.8%)
patients with a median serum sodium concentration of
132 (IQR130-134) mmol/l. The hyponatremic patient
group had significantly different demographic characteris-
tics: more patients were women and from African descent
with a lower prevalence of homo-bisexual orientation.
A significantly higher proportion of patients with
hyponatremia were hospitalized at first contact [72.3%
versus (vs) 20.0%]. In comparison with people without
hyponatremia, those with hyponatremia had significantly
more severe HIV disease with a lower CD4 cell countTable 1 Main characteristics of hyponatremic and normonatremic p
Characteristics Total (N = 1196)
Age (years)a 36.8 ± 10.7
Female gender (n) 445 (37.2%)
African ethnicity (n) 612 (51.2%)
Homo-bisexual orientation (n) 395 (33.0%)
Natremia (mmol/l)b 139.0 (136.0-141.0)
Hospitalization at first contact (n) 332 (27.7%)
Acquired immunodeficiency syndrome (AIDS) (n) 215 (18.0%)
CD4 cell count (/μl)a 371.8 ± 275.3
CD4 cell count < 350/μl (n) 611 (51.1%)
CD4 nadir (/μl)a 362.8 ± 267.6
CD4 nadir < 200/μl (n) 360 (30.1%)
HIV viral load (copies/ml)b 71600 (13500–100000
HIV viral load > 100 000 copies/ml (n) 465 (38.9%)
Hepatitis B (n) 69 (5.8%)
Hepatitis C (n) 69 (5.8%)
Fib 4 score > 3.25 (n) 77 (6.4%)
Anemia (n) 597 (50%)
Hyperlipidemia (n) 418 (34.9%)
Mean triglyceridemia (mg/dl)a 111.1 ± 68.5
Mean estimated glomerular filtration ratec (ml/min)a 112.3 ± 23.3
Diabetes mellitus (n) 52 (4.3%)
Antihypertensive drugs (n) 39 (3.3%)
amean ± standard deviation
bmedian (interquartile range)
cestimated using CKD-EPI equation [36](208 ± 198/μl vs 400.4 ± 277/μl), about twice the HIV
viral load and an approximatively four-fold higher preva-
lence of AIDS. No significant differences in the co-
existence of a hepatitis B or C infection were noted
between the two groups but hyponatremic patients had
more frequently a high FIB-4 index (>3.25) suggestive of
a more prevalent liver fibrosis.
Baseline serum sodium concentration as a continuous
variable was also associated with CD4 cell count (Fig. 1).
A decrease in natremia was positively correlated with a
decreasing CD4 cell count (Pearson Correlation Coeffi-
cient = 0.2993; P < 0.0001). Furthermore, natremia corre-
lated negatively with the HIV viral load (Pearson
Correlation Coefficient = −0.1174; P < 0.0001; Fig. 2).Association of hyponatremia with hospitalization rate and
mortality
About 70% of patients were started on cART after inclu-
sion in the cohort. The median follow-up time was 36.0
(IQR 9.0-80.0) months and the incidence of patients with
loss to follow-up was 8.2 [95% confidence interval (CI)atients
Na < 135 mmol/l (N = 177) Na ≥ 135 mmol/l (N = 1019) P-value
37.4 ± 10.0 36.7 ± 10.9 0.238
90 (50.8%) 355 (34.8%) <0.0001
125 (70.6%) 487 (47.8%) <0.0001
26 (14.7%) 369 (36.2%) <0.0001
132.0 (130.0-134.0) 139.0 (137.0-141.0) <0.0001
128 (72.3%) 204 (20.0%) <0.0001
89 (50.3%) 126 (12.4%) <0.0001
207.5 ± 197.7 400.4 ± 277.0 <0.0001
143 (80.8%) 468 (45.9%) <0.0001
200.8 ± 184.1 391.2 ± 269.9 <0.0001
106 (59.9%) 254 (24.9%) <0.0001
) 100000 (55000–313500) 58750 (11800–100000) <0.0001
104 (58.7%) 361 (35.4%) <0.0001
14 (7.9%) 55 (5.4%) 0.223
12 (6.8%) 57 (5.6%) 0.478
28 (15.8%) 49 (4.8%) <0.0001
138 (78%) 459 (45%) <0.0001
58 (32.8%) 360 (35.3%) 0.550
132.4 ± 79.9 108.0 ± 66.0 <0.0001
111.4 ± 29.3 112.5 ± 22.0 0.227
14 (7.9%) 38 (3.7%) 0.0254
4 (2.2%) 35 (3.4%) 0.645
Fig. 1 Scatter plot of natremia and CD4 count. A decrease in serum sodium is positively correlated with a decreasing CD4 cell count (Pearson
Correlation Coefficient = 0.2993; P < 0.0001)
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hyponatremic and normonatremic patients).
Patients lost to follow-up were significantly younger,
more frequently of female gender, hetero-sexual and of
African ethnicity. They were more often hospitalized at
first contact and had a shorter median time to a first
hospitalisation. However, there was no significantFig. 2 Scatter plot of natremia and HIV viral load. A decrease in serum sod
Correlation Coefficient = −0.1174; P < 0.0001)difference in the prevalence of hyponatremia, CD4 count
or AIDS (see Additional file 1).
Hyponatremic patients had a higher incident
hospitalization rate of 785/1000 patient-years (95% CI
725 to 845) compared to 370/1000 patient-years (95% CI
352 to 388) in normonatremic patients (incidence rate
ratio: 2.12, 95% CI 1.94-2.32; P < 0.0001) and a shorterium is negatively correlated with an increasing HIV viral load (Pearson
Table 2 Outcomes in hyponatremic and normonatremic patients
Characteristics Total (N = 1196) Na < 135 mmol/l (N = 177) Na≥ 135 mmol/l (N = 1019) P-value
Combined antiretroviral therapy (n) 845 (70.6%) 130 (73.4%) 715 (70.2%) 0.421
Follow-up (months)a 36.0 (9.0-80.0) 41.0 (4.0-115.0) 35.0 (10.0-77.0) 0.554
Loss to follow-up/100 patient-years (95% CI) 8.2 (7.5-9.1) 8.4 (7.4-9.1) 8.2 (6.5-10.6) 0.870
Deaths (n) 63 (5.3%) 24 (13.5%) 39 (3.8%) <0.0001
Death rate/1000 patient-years (95% CI) 12.5 (9.6-16.0) 28.3 (18.1-42.2) 9.33 (6.6-12.7) <0.0001
Hospitalization rate/1000 patient-years (95% CI) 440 (422–458) 785 (725–845) 370 (252–388) <0.0001
Mean number of hospitalizations per patient (n)b 2.2 ± 4.9 4.3 ± 9.5 1.8 ± 3.3 <0.0001
Median time to death (months)a 12.0 (3.0-34.0) 6.0 (2.0-22.5) 14.0 (4.0-39.0) 0.169
Median time to first hospitalization (months)a,c 12.0 (2.0-28.0) 2.0 (0.0-12.0) 13.0 (2.0-29.0) 0.0012
amedian (interquartile range)
bmean ± standard deviation
cexcluding patients hospitalized at first contact
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13.0 [2.0-29.0] months).
In the overall study population, 63 patients (5.3%) died
during follow up with an increased mortality for patients
with hyponatremia at baseline (13.5% vs 3.8%; P <
0.0001). At the univariate level patients with hyponatre-
mia had a significantly increased incident mortality rate
of 28.3/1000 patient-years (95% CI 18.15-42.16) com-
pared to 9.33/1000 patient-years (95% CI 6.63-12.75) for
normonatremic patients (incidence rate ratio: 3.04, 95%
CI 1.80-5.03; P < 0.0001). The Kaplan-Meier estimates of
survival differed significantly between the two natremia
groups (log-rank test: P < 0.001; Fig. 3). Adjusting hypo-
natremia for other risk factors of patient death in aFig. 3 Kaplan-Meier estimates of survival by natremia group. Population at risk
3-year and 5-year cumulative survival rates were 98.1%± 0.4%, 97.8%± 0.5%, 96
91.4%± 2.3%, 89.2%± 2.6%, 85.8%± 3.0%, 83.8%± 16.2% respectively in the hypmultivariate Cox model reduced the hazard ratio from
3.94 to 1.03 (95% CI 0.54-1.97), close to unity and no
longer statistically significant (Table 3; Title: Risk factors
for mortality of patients in univariate/multivariate Cox’s
proportional hazard models).
AIDS at inclusion, a CD4 count < 350/μl and hepatitis
C were independent predictors of patient death in the
multivariate model. In a supplemental analysis the popu-
lation was restricted to the 356 patients who had ad-
vanced HIV disease with a CD4 count < 200/μl. A total
of 106 (29.8%) of patients had hyponatremia which was
significantly associated with mortality in univariate ana-
lysis but remained non significant in the multivariate
model (see Additional file 2).during the follow-up is tabulated below the graph. The 6-months, 1-year,
.3% ± 0.7%, 95.5%± 4.5% respectively in normonatremic patients versus
onatremic group. Hypothesis testing by the log-rank test with P< 0.0001
Table 3 Risk factors for mortality of patients in univariate/multivariate Cox’s proportional hazard models
Univariate Model Multivariate Model
Risk factors Hazard ratio (95% Confidence interval) P-value Hazard ratio (95% Confidence interval) P-value
Age < 35 years 0.51 (0.29-0.87) 0.014 0.91 (0.48-1.73) 0.782
Female gender 1.68 (1.01-2.80) 0.045 1.65 (0.86-3.16) 0.132
African ethnicity 1.29 (0.77-2.15) 0.366
Homo-bisexuel orientation 0.28 (0.13-0.59) 0.0003 0.90 (0.34-2.34) 0.827
Natremia < 135 mmol/l 3.94 (2.30-6.74) <0.0001 1.03 (0.54-1.97) 0.935
AIDS 8.83 (5.18-15.06) <0.0001 5.24 (2.59-10.62) <0.0001
CD4 cell count < 350/μl 11.71 (4.66-29.43) <0.0001 6.58 (1.89-23.06) 0.003
HIV viral load > 100 000 copies/ml 3.36 (1.87-6.03) <0.0001 1.15 (0.56-2.37) 0.702
Hepatitis B 0.23 (0.032-1.71) 0.172
Hepatitis C 2.54 (1.15-5.60) 0.0259 2.70 (1.172-6.23) 0.02
Fib4 score > 3.25 3.84 (1.95-7.55) <0.0001 1.69 (0.77-3.74) 0.192
Anemia 4.30 (2.95-6.27) <0.0001 1.15 (0.75-2.84) 0.263
Hyperlipidemia 0.93 (0.54-1.59) 0.892
Diabetes mellitus 4.22 (1.96-9.11) 0.0011 2.07 (0.88-4.85) 0.096
Inclusion period 1998-2004 2.54 (1.52-4.25) 0.0004 1.32 (0.72 – 2.42) 0.372
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prevalence of hyponatremia over time
Long term follow-up allowed to evaluate the evolution
of hyponatremia over the last 15 years. The prevalence
of hyponatremia clearly decreased over time: in the
1998–2004 period, 27.0% of the patients had hyponatre-
mia at baseline compared to only 8.0% in the more re-
cent period (2005–2013). Interestingly, there was a
parallel evolution of mortality decreasing from 8.4 to
3.5% as well as AIDS (prevalence decreased from 23.5 to
14.9% in the recent period; P = 0.0003). Moreover, in the
1998–2004 period, patients were more frequently hospi-
talized at first contact (39.7% vs 21.2%; P < 0.0001) and
more often admitted during follow-up (mean number of
hospitalizations per patient: 3.3 ± 6.9 vs 1.6 ± 3.0; P <
0.0001). As the period is clearly associated with both
hyponatremia and survival it might act as a confounder
of the effect of hyponatremia on survival. However, the
inclusion of the period as variable in the Cox propor-
tional hazard model did not influence our results signifi-
cantly (Table 3).
Demographically our patient population did also
change over time: patients in the period 2005–2013
were less frequently of female gender (31.8% vs
46.9%) and African ethnicity (44.8% vs 62.7%) but sig-
nificantly more of homo-bisexual orientation (40.8%
vs 19.0%). Finally, the incidence of patients lost to
follow up in the earlier 1998–2004 period was higher
compared to the more recent period 2005–2013 (11.2
95% CI 9.0-13.8 vs 8.1 95% CI 7.0-9.3 per 100
patient-years, P = 0.012).Causes of death
About half of the patients died of an AIDS-related cause
(AIDS with an ongoing active infection or malignancy).
There were no significant differences between the two
groups of natremia (AIDS-related deaths in hyponatre-
mic patients: 54.1% versus 46.1% in normonatremic pa-
tients, P = 0.609). Four patients died from parasitic or
fungal infections, 5 from bacterial infections such as tu-
berculosis or sepsis, 13 from AIDS-related malignancies
and 3 from neurological causes in relation with AIDS (2
multifocal leucoencephalitis and 1 cerebral hemorrhage
in the context of disseminated tuberculosis). Six patients
died from complex associations of AIDS related infec-
tion and cancer without possibility to clearly identify the
principal cause of death. Nine out of 31 deaths impli-
cated disease of the central nervous system (29% of
AIDS-related deaths). There was no difference in the
number of deaths from central nervous system-related
causes in patients with hyponatremia (31%) as compared
to patients with normonatremia (28%; P = 1.000).
Other causes of death included not HIV related infec-
tion (17.5%), not HIV related malignancy (7.9%), active
substance abuse (3.2%), chronic viral hepatitis (1.6%), is-
chemic heart disease (1.6%) or other (6.3%). The causes of
death were unclassified or unknown in 4 patients (6.3%).
Causes of hospital admission
In the overall cohort leading causes of hospital admis-
sion were bacterial infections (338 admissions, 14.6%),
malignancies (206 admissions, 8.9%), respiratory (187
admissions, 8.1%), AIDS-related (134 admissions, 5.8%),
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4.7%), neurological (105 admissions, 4.5%) and parasitic
infections (90 admissions, 3.9%). The cause of hospital
admission was unknown in 403 admissions (17.4%). Pa-
tients with hyponatremia had an approximatively 5-fold
increased risk of being admitted for an AIDS-related
cause (odds ratio [OR] = 5.15, 95% CI 3.28-8.08; P <
0.0001) or endocrine/metabolic causes (OR = 5.07, 95%
CI 1.68-15.27; P < 0.007); a 4.5-fold increased risk for
bacterial infections (OR = 4.49, 95% CI 3.16-6.37; P <
0.0001); a 4-fold increased risk for respiratory causes
(OR = 4.04, 95% CI 2.66-6.12; P < 0.0001); a 3-fold in-
creased risk for malignancies (OR = 3.00, 95% CI 1.67-
5.41; P = 0.0006); a 2-fold risk for drug toxicities (OR =
2.11, 95% CI 1.04-4.28; P = 0.045), for parasitic infections
(OR = 2.05, 95% CI 1.12-3.77; P = 0.024), for digestive
(OR = 1.86, 95% CI 1.08-3.19; P = 0.033) or gynaeco-
logical reasons (OR = 1.85, 95% CI 1.13-3.05; P = 0.018)
(see Additional file 3).
Evolution of natremia during follow up
Among patients who had hyponatremia at baseline,
19.2% of patients still had hyponatremia at last contact
compared to 2.5% in baseline normonatremic patients
(P < 0.0001). Interestingly, hyponatremia at last contact
was significantly more prevalent in deceased patients
than in living patients (21.3% vs 3.9%; P < 0.0001).
Discussion
The present study agrees with previous reports in HIV
patients that baseline hyponatremia is associated with an
increased risk of mortality in univariate analysis without
adjustment for confounders [26–28]. All of these studies
originated from Africa or Asia and had relatively short
follow up periods and higher mortality rates than ob-
served in North American or European populations. A
prospective cohort study of 661 HIV infected women in
sub-Saharian Africa demonstrated that baseline hypona-
tremia was associated with a more than four-fold in-
crease in the risk of death [26]. This study had a limited
follow-up of one year after initiation of antiretroviral
therapy in patients with a high mortality (8%) mainly
due to tuberculosis (32%). More recently a prospective
cohort study of 141 hospitalized patients with advanced
stages of HIV infection in China showed that baseline
hyponatremia was present in 28.4% of patients and inde-
pendently associated with three-fold increase of death
within six months after admission [27]. In this study,
72.9% of patients had advanced HIV disease [World
Health Organization (WHO) stage 4] and 21.3% of pa-
tients died during the first six months of admission
which is higher than the short-term mortality rates in
other studies [29]. Other limitations included the small
sample size (141 patients) and the short follow-up timeof 6 months. Another Chinese study by Xu included 387
cART-naïve hospitalized patients with variable follow-up
times from 1 week to 72 months [28]. Those patients
had a high prevalence of hyponatremia (53.2%), ad-
vanced HIV disease (84.2% were WHO stage III or IV)
and a low overall survival (3-year cumulative survival
rates were 47.8% ± 68.5% for patients with moderate/se-
vere hyponatremia, 59.8% ± 65.0% for those with mild
hyponatremia and 78.2% ± 63.8% for normonatremic pa-
tients). Reporting of mortality in this cohort was also re-
stricted to AIDS-related death.
Interestingly, in contrast to the previously cited stud-
ies, hyponatremia was not an independent risk factor for
mortality in our analysis, even after restricting the ana-
lysis to patients with advanced HIV disease (CD4 < 200/
μl). In fact, adjustement for AIDS as only covariate in
the multivariate analysis completely canceled the effect
of hyponatremia on mortality. This suggests that hypo-
natremia might be a marker of severe HIV-related dis-
ease and not directly implicated in the increased
incidence rate of patient death. This is supported by the
fact that patients with hyponatremia at baseline had a
significantly more severe HIV disease with lower CD4
count, higher number of hospitalisations in the follow-
up and increased prevalence of AIDS compared to pa-
tients with a normal serum sodium concentration (50.3
vs 12.4%). Xu and collegues have nicely demonstrated
that natremia is negatively correlated with WHO stage
[28]. In their study patients with advanced WHO stages
had a significantly lower natremia: mean serum sodium
concentration was 136.7 ± 5.4 mmol/l in patients in
WHO stage I/II, 132.8 ± 6.6 mmol/l in stage III and
131.7 ± 6.3 mmol/l in stage IV (F = 14.586; P < 0.001).
Our analysis confirms the previously reported significant
positive correlation by Xu between the serum sodium
concentration and CD4 cell count. Furthermore a de-
crease in natremia is negatively correlated with an in-
creasing HIV viral load which is also an argument for
the hypothesis of hyponatremia as a marker of severity.
It is also of interest to note that increased mortality in
hyponatremic patients is mainly seen during the first
6 months of follow-up, with Kaplan-Meier survival curve
thereafter showing a parallel decrease in survival be-
tween the two natremia groups. Patients with a low
serum sodium at baseline have an increased mortality in
the first months because of a more advanced HIV dis-
ease but on the long term hyponatremia at baseline does
not appear to be predictive of mortality.
Another finding which was quite unexpected is that
there were not significantly more HIV-related deaths in
patients with hyponatremia than in normonatremic pa-
tients at baseline (66.7% versus 48.7%; P = 0.198). This
supports the idea of hyponatremia as a general marker of
disease severity which is not specific for HIV. In fact, the
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higher in deceased patients than in living patients (21.3%
vs 3.9%; P < 0.0001). The idea that hyponatremia does not
contribute directly to mortality but is merely a surrogate
marker for the severity of the underlying disease is also
supported by studies in patients with advanced heart fail-
ure [30] and liver cirrhosis [31]. Although hyponatremia
has been associated with mortality in various settings,
there is an active debate in the literature whether hypona-
tremia contributes directly to mortality and if so, how this
effect would be mediated. Until now no study has convin-
cingly shown this direct contribution to mortality and it
also remains unclear whether correcting hyponatremia
improves outcomes [32].
Our study has limitations. First, we were not able to
exclude pseudohyponatremia which is a laboratory arte-
fact that occurs when abnormally high concentrations of
lipids or proteins such as gammaglobulins in the blood
interfere with the accurate measurement of sodium [33].
As hypergammaglobulinemia is a frequent occurrence in
HIV patients, pseudohyponatremia might be an import-
ant and likely underdiagnosed phenomenon in this pa-
tient population [34]. Pseudohyponatremia can be ruled
out by the measurement of a normal serum osmolality
which was not done routinely in our study population. A
second limitation is that the demographic characteristics
of the study population and the prevalence of hyponatre-
mia changed over time. However, mortality rates
remained stable during the entire study period without
significant interaction with time, so respect of propor-
tionality in time can be assumed. Furthermore, to adress
the issue of differences in follow-up time we calculated
incidence rates to take into account the time at risk. Fi-
nally, the study suffered from a large proportion of pa-
tients lost to follow-up (incidence of 8.24 per 100
person-years of follow-up) which is higher than the 3.72
per 100 person-years of loss to follow-up reported from
an international observational study [35]. However, there
was considerable variation in loss to follow-up among
the different countries that participated in the EuroSIDA
study, varying from 0.67 to 13.35. The loss of follow-up
in our cohort is probably mainly explained by socio-
demographic factors as patients lost to follow-up were
significantly younger, more frequently hetero-sexual and
of African ethnicity (61%).
This might be a source of selection bias as patients
lost to follow-up may be less healthy and therefore more
likely to die leading to an underestimation of the study
outcome. However, patients who dropped out had no
significant clinical differences regarding the prevalence
of baseline hyponatremia, CD4 count and AIDS. In
addition the proportion of patients lost to follow-up did
not differ among those with and without baseline
hyponatremia.Conclusion
In conclusion, this study shows that hyponatremia is a
marker of the severity of HIV-disease but not an inde-
pendent risk factor for mortality as suggested by previ-
ous publications. Hyponatremic HIV patients had a
lower CD4 cell count, a higher prevalence of AIDS and
were more frequently hospitalized at first contact com-
pared to normonatremic patients. Furthermore, during
the follow-up period patients with hyponatremia had a
shorter median time to a first hospitalization and an in-
creased incident hospitalization and mortality rate. HIV-
patients with a low serum sodium at baseline might
benefit from a close follow-up to improve outcomes.
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Clinical and socio-demographic factors in patients lost to follow-up
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of hyponatremia with mortality in a restricted population of patients who
had advanced HIV disease with a CD4 count < 200/μl. (DOCX 52 kb)
Additional file 3: Causes of hospital admission in hyponatremic and
normonatremic patients. Causes of hospital admission taking only into
account the first admission per patient. (DOCX 68 kb)
Abbreviations
AIDS: Acquired immunodeficiency syndrome; ARC: AIDS-related complex;
cART: Combined antiretroviral therapy; CI: Confidence interval; HIV: Human
immunodeficiency virus; IQR: Interquartile range; vs: Versus; WHO: World
Health Organization
Acknowledgements
We thank Evi Nagler MD PhD for critical reading of the manuscript and
many helpful comments and suggestions.
Funding
None.
Availability of data and materials
All raw data are available by request to Delforge Marc (marc_delforge@stpierre-
bru.be).
Authors’ contributions
PB has participated in the development of the research question and the
study protocol, data collection, interpretation of the results and in the
writing of the paper. MD has participated in data collection, data analysis
and interpretation of the results. MG has participated in the data collection
and interpretation of the results. KMW has participated in the development
of the research question, setting up the study protocol, data analysis,
interpretation of the results and writing of the paper. SDW has participated
in the development of the research question, setting up the study protocol,
interpretation of the results and writing of the paper. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Braconnier et al. BMC Infectious Diseases  (2017) 17:98 Page 10 of 10Ethics approval and consent to participate
The study was designed in accordance with the ethical standards of the
Hôpital St Pierre Ethics committee. Patients consented at the time of
inclusion in the Brussels St Pierre Cohort that their medical data would be
collected in databases for research purposes.
Author details
1Department of Infectious Diseases, AIDS Reference Center, Saint-Pierre
University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
2Department of Nephrology, Universitair Ziekenhuis Brussel, Vrije Universiteit
Brussel, Brussels, Belgium. 3Department of Nephrology, Centre Hospitalier
Universitaire Brugmann, Brussels, Belgium.
Received: 4 June 2016 Accepted: 5 January 2017References
1. Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of
hyponatremia. Am J Med. 2006;119(7 Suppl 1):S30–5.
2. Hawkins RC. Age and gender as risk factors for hyponatremia and
hypernatremia. Clin Chim Acta. 2003;337:169–72.
3. Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild,
moderate, and severe hyponatremia. Am J Med. 2009;122(9):857.
4. Gankam-Kengne F, Ayers C, Khera A, de Lemos J, Maalouf NM. Mild
hyponatremia is associated with an increased risk of death in an ambulatory
setting. Kidney Int. 2013;83(4):700–6.
5. Dargie HJ, Cleland JG, Leckie BJ, Inglis CG, East BW, Ford I. Relation of
arrhythmias and electrolyte abnormalities to survival in patients with severe
chronic heart failure. Circulation. 1987;75(5, pt 2):IV98–IV107.
6. Arroyo V, Rodes J, Gutierrez-Lizarraga MA, Revert L. Prognostic value of
spontaneous hyponatremia in cirrhosis with ascites. Am J Dig Dis. 1976;
21(3):249–56.
7. Liamis G, Rodenburg EM, Hofman A, Zietse R, Stricker BH, Hoorn EJ.
Electrolyte disorders in community subjects: prevalence and risk factors. Am
J Med. 2013;126(3):256–63.
8. Akalin E, Chandrakantan A, Keane J, Hamburger RJ. Normouricemia in the
syndrome of inappropriate antidiuretic hormone secretion. Am J Kidney Dis.
2001;37(1):E8.
9. Glassock RJ, Cohen AH, Danovitch G, Parsa KP. Human immunodeficiency
virus (HIV) infection and the kidney. Ann Intern Med. 1990;112(1):35.
10. Milger K, Fleig V, Kohlenberg A, Discher T, Lohmeyer J. Neurosyphilis
manifesting with unilateral visual loss and hyponatremia: a case report. BMC
Infect Dis. 2011;11:17.
11. Vitting KE, Gardenswartz MH, Zabetakis PM, et al. Frequency of
hyponatremia and nonosmolar vasopressin release in the acquired
immunodeficiency syndrome. JAMA. 1990;263(7):973.
12. Tang WW, Kaptein EM, Feinstein EI, Massry SG. Hyponatremia in hospitalized
patients with the acquired immunodeficiency syndrome (AIDS) and the
AIDS-related complex. Am J Med. 1993;94(2):169–74.
13. Cusano AJ, Thies HL, Siegal FP, Dreisbach AW, Maesaka JK. Hyponatremia in
patients with acquired immune deficiency syndrome. J Acquir Immune
Defic Syndr. 1990;3(10):949–53.
14. Palella Jr FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA,
et al. Declining morbidity and mortality among patients with advanced
human immunodeficiency virus infection. HIV Outpatient Study
Investigators. N Engl J Med. 1998;338(13):853–60.
15. Friis-Moller N, Sabin CA, Weber R, d’Arminio Monforte A, El-Sadr WM, Reiss
P, et al. Combination antiretroviral therapy and the risk of myocardial
infarction. The data collection on adverse events of anti-HIV drugs (D:A:D)
study group. N Engl J Med. 2003;349(21):1993–2003.
16. Collaboration of Observational HIV Epidemiological Research Europe
(COHERE) Study group, Bholius J, Schmidlin K, Costagliola D, Fätkenheuer G,
May M, Caro Murillo AM, et al. Prognosis of HIV-associated non-Hodgkin
lymphoma in patient starting combination antiretroviral therapy. AIDS. 2009;
23(15):2029–37.
17. Podlekareva D, Mocroft A, Dragsted UB, Ledergerber B, Beniowski M,
Lazzarin A, et al. for the EuroSIDA study group. Factors associated with
development of opportunistic infections in HIV-1 infected adults with high
CD4 cell counts: a EuroSIDA study. J Infect Dis. 2006;194(5):663–41.18. CDC. 1993 revised classification system for HIV infection and expanded
surveillance case definition for AIDS among adolescents and adults. MMWR.
1992;41(No. RR-17):1–19.
19. Mocroft A, Kirk O, Barton SE, Dietrich M, Proenca R, Colebunders R, et al.
Anaemia is an independent predictive marker for clinical prognosis in HIV-
infected patients from across Europe. EuroSIDA study group. AIDS. 1999;
13(8):943–50.
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults. Executive summary of the third report of the national
cholesterol education program (NCEP) expert panel on detection,
evaluation, and treatment of high blood cholesterol in adults (adult
treatment panel III). JAMA. 2001;285(19):2486–97.
21. Summary of revisions for the 2010 Clinical Practice Recommendations. Diab
Care. 2010;33:Suppl 1:S3. doi: 10.2337/dc10-S003.
22. Van der Helm J, Geskus R, Sabin C, Meyer L, Del Amo J, Chêne G, et al.
CASCADE collaboration in EuroCoord. Effect of HCV infection on cause-
specific mortality after HIV seroconversion, before and after 1997.
Gastroenterology. 2013;144(4):760. e2.
23. Sterling RK, et al. Development of a simple noninvasive index to predict
significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;
43(6):1317–25.
24. Mussini C, Lorenzini P, Puoti M, Lichtner M, Lapadula G, Di Giambenedetto
S, et al. ICONA foundation study group. Prognostic value of the fibrosis-4
index in human immunodeficiency virus type-1 infected patients initiating
antiretroviral therapy with or without hepatitis C virus. PLoS One. 2015;
10(12):e0140877.
25. Ford N, Shubber Z, Meintjes G, Grinsztejn B, Eholie S, Mills EJ, et al. Causes
of hospital admission among people living with HIV worldwide: a
systematic review and meta-analysis. Lancet HIV. 2015;2(10):e438–44.
26. Dao CN, Peters PJ, Kiarie JN, Zulu I, Muiruri P, Ong’ech J, et al.
Hyponatremia, hypochloremia, and hypoalbuminemia predict an increased
risk of mortality during the first year of antiretroviral therapy among HIV-
infected Zambian and Kenyan women. AIDS Res Hum Retroviruses. 2011;
27(11):1149–55.
27. Wen Y, Zhou Y, Wang W, Wang Y, Lu X, Sun CM, et al. Baseline factors associated
with mortality within six months after admission among hospitalized HIV-1
patients in Shenyang, China. Intern Med. 2014;53(21):2455–61.
28. Xu L, Ye H, Huang F, Yang Z, Zhu B, Xu Y, et al. Moderate/severe
hyponatremia increases the risk of death among hospitalized Chinese
human immunodeficiency virus/acquired immunodeficiency syndrome
patients. PLoS One. 2014;9(10):e111077.
29. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al.
Antiretroviral therapy in lower income countries (ART-LINC) collaboration;
ART cohort collaboration (ART-CC) groups. Mortality of HIV-1-infected
patients in the first year of antiretroviral therapy: comparison between low-
income and high-income countries. Lancet. 2006;367(9513):817–24.
30. Mohammed AA, van Kimmenade RR, Richards M, et al. Hyponatremia,
natriuretic peptides, and outcomes in acutely decompensated heart failure:
results from the International Collaborative of NT-ProBNP Study. Circ Heart
Fail. 2010;3(3):354–61.
31. Porcel A, Diaz F, Rendon P, Macias M, Martin-Herrera L, Giron-Gonzalez JA.
Dilutional hyponatremia in patients with cirrhosis and ascites. Arch Intern
Med. 2002;162(3):323–8.
32. Hoorn EJ, Zietse R. Hyponatremia and mortality: moving beyond
associations. Am J Kidney Dis. 2013;62(1):139–49.
33. Rose BD, Post TW. Clinical physiology of acid–base and electrolyte disorders.
5th ed. New York: McGraw-Hill; 2001. p. 699.
34. Garibaldi BT, Cameron SJ, Choi M. Pseudohyponatremia in a patient with
HIV and hepatitis C coinfection. J Gen Intern Med. 2008;23(2):202–5.
35. Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A, Chentsova N, et al. EuroSIDA
study group. Loss to follow-up in an international, multicentre observational
study. HIV Med. 2008;9(5):261–9.
36. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. CKD-
EPI (chronic kidney disease epidemiology collaboration). a new equation to
estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.
